Background And Objectives: Timely access to specialist care is crucial in expeditious diagnosis and treatment. Our study aimed to assess the time patients wait from being referred by a physician to seeing a neurologist using Medicare data. Specifically, we evaluated differences in access related to sex, race/ethnicity, geography, and availability of neurologists.
Methods: We conducted a cross-sectional analysis using a 2018-2019 Medicare sample of patients who had a new patient visit to a neurologist. Our primary outcome was the wait time between their last visit with the referring physician and their first visit with the neurologist (the index neurologist visit). We also looked at the time between the first visit for a neurologic condition and the index neurologist visit for that same condition. We used a linear mixed-effects model to identify the factors associated with the wait time, considering the patients' hospital referral regions (HRRs).
Results: We identified 163,313 Medicare beneficiaries who had a new patient visit with a neurologist in 2018-2019 after their physician referred them. Their average age was 73.8 (SD 10.7). The median (interquartile range) wait time to the index neurologist visit was 34 days (15-70), and 18% of patients waited >90 days. Patients with multiple sclerosis (MS) had to wait an average of 29.4 days longer, patients with epilepsy waited 10.4 days longer, and patients with Parkinson disease (PD) waited 9.3 days longer than patients with back pain. There were no significant differences in wait times across race/ethnicity and sex. Our study also showed no significant differences in wait times across regions with varying levels of neurologist availability. When patients visited a neurologist located outside of their residential or referring physician's HRR, the wait time was extended by an average of 11 days.
Discussion: We found that, patients waited 34 days to see a neurologist after their physician referred them while 18% of them waited more than 90 days. Factors such as sex, race/ethnicity, and neurologist availability did not significantly affect timely access to neurologists. Patients with MS, epilepsy, and PD had longer wait times, despite needing the specialized care that neurologists can provide. This highlights the need for innovative approaches to improve timely access to neurologists.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1212/WNL.0000000000210217 | DOI Listing |
J Clin Oncol
January 2025
Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA.
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progression in a protocol-defined wait-and-see subset analysis of eligible patients where treatment resumption with larotrectinib was allowed if disease progressed. We also assessed the safety and efficacy of larotrectinib in all pediatric patients with sarcoma.
View Article and Find Full Text PDFClin Child Psychol Psychiatry
January 2025
Department of Psychology, Stockholm University, Sweden.
Internalizing and externalizing psychiatric disorders among children are common and debilitating, affecting family interactions, learning and peer relations. The aim of the present quasi-randomised pilot-study was to investigate preliminary effects of a mentalization-based time-limited treatment (MBT-C) for children with mixed psychiatric disorders. The trial comprised 17 children, aged 4-11 with mixed disorders, and their parents, admitted to an outpatient psychotherapy clinic.
View Article and Find Full Text PDFLife (Basel)
January 2025
1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, "Papageorgiou" Hospital, 564 29 Thessaloniki, Greece.
(1) Background: Suspicious adnexal masses should be referred to gynecological oncology units. However, when surgery waiting lists are prolonged, these patients usually suffer from a delay in surgery. This could have a negative impact on their prognosis when the final diagnosis is ovarian cancer (OC).
View Article and Find Full Text PDFInt J Health Plann Manage
January 2025
Emergency Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
The objective of this paper is to explore how an emergency department in Argentina collected patient experience perspectives using varied tools to inform improvement activities. A case report of a mixed-methods assessment of patient experiences to inform quality improvement in an Emergency Department in Argentina. This study was conducted from July 2022 to December 2023 at Hospital Italiano de Buenos Aires, Argentina.
View Article and Find Full Text PDFBMC Womens Health
January 2025
School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Ovarian cancer is a leading cause of mortality worldwide. The third most prevalent gynecological cancer globally, following cervical and uterine cancer, and the third leading cause of cancer-related mortality among women in Sub-Saharan Africa, including Ethiopia. The time ovarian cancer patients have to wait between diagnosis and initiation of treatment are the indicators of quality in cancer care and influence patient outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!